source
- FDA urges Amgen to withdraw Tavneos after alleging data manipulation by former developerThe FDA has sent a formal letter to Amgen recommending that the company pull its drug Tavneos from the market. The agency says new information shows the original approval filings from ChemoCentryx…
- FDA says trial manipulation undermines approval of ChemoCentryx's Tavneos, now owned by AmgenThe U.S. Food and Drug Administration has announced that it believes the pivotal trial supporting the approval of Tavneos was manipulated. The agency says ChemoCentryx, which was acquired by Amgen…